Wei Zhou

Wei Zhou

Auto-generated profile, based on publicly available information

Wei Zhou

Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
ZWZhenxing Wang
Zhenxing Wang
TYTong Yu
Tong Yu
YHYapeng Hou
Yapeng Hou
WZWei Zhou
Wei Zhou
YDYAN DING
YAN DING
HNHongguang Nie
Hongguang Nie
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a serious clinical common disease, which may be caused by a variety of pathological factors and can induce a series of serious complications. There is still no specific and effective method for the treatment of ALI/ARDS. Mesenchymal stem cells (MSCs) have been one of the treatment methods for ALI, which can regulate related signal pathways such as PI3K/AKT, Wnt, and NF-κB to reduce inflammation. MSCs exist in a variety of tissues and have the ability of self-renewal and differentiation, which can be activated by specific substances or environments and home to the site of tissue damage, where they differentiate into new tissue cells and repair the damage. Both exosomes and cytokines involving the paracrine mechanism of MSCs have benefits on the treatment of ALI. Lung organoids produced by 3D culture technology can simulate the characteristics of the lung and help to research the pathophysiological process of ALI. This review summarizes the mechanisms by which MSCs treat ALI/ARDS and expects to use 3D models for future challenges in this field.